Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Concord Drugs Ltd (538965)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 538965 NSE: Pharmaceuticals & Drugs | Small Cap | Concord Drugs Share Price

₹78.33 2.50 (3.30%)

As on 25-Sep'26 16:59

Concord Drugs Ltd (538965)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 538965 NSE: Pharmaceuticals & Drugs | Small Cap | Concord Drugs Share Price

₹78.33 2.50 (3.30%)

As on 25-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹103 Cr.
Current Price
₹78.3
52-Week Low / High
₹61 / 93
TTM EPS
₹1.6
TTM Sales
₹86.1 Cr.
Book Value per Share
₹37.7
P/E Ratio
50.32
Higher than its 5-year historical median
Industry PE
54.9
Price to Book (P/B)
2.08
Higher than its 5-year historical median
Price to Sales (P/S)
1.20
Higher than its 5-year historical median
EV/EBITDA
19.92
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
0.99%
Underperforms industry median
Return on Capital Employed (ROCE)
5.19%
Underperforms industry median
Return on Assets (ROA)
0.54%
Operating Profit Margin
9.1%
Net Profit Margin
0.74%
Gross Profit Margin
4.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-14.63%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
2.23%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-27.66%
Asset Quality
Promoter Holding
45.08%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹36 Cr.
Equity
₹13.2 Cr.
Face Value
₹10
All Time Low / High
₹11.68 / 92.52

Concord Drugs stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Somewhat Overvalued

Check Valuation charts

Price Trend

Weak
Check Price chart
Q.1 Is Concord Drugs Ltd a good quality company?
Concord Drugs Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Concord Drugs Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Concord Drugs Ltd vs industry peers?
Concord Drugs Ltd revenue CAGR is -8.45%, compared to the industry median CAGR of 0%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Concord Drugs Ltd?
Promoters hold 45.08% of the Concord Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Concord Drugs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 2.4% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Concord Drugs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ15.9%8.8%7.5%6.2%6.1%15.7%9.3%6%4.5%4.7%-
Value Creation
Index ⓘ		0.1-0.4-0.5-0.6-0.60.1-0.3-0.6-0.7-0.7-

Growth Parameters ⓘ
Sales ⓘ50.757.551.848.151.351.45951.343.336.983
Sales YoY Gr.-13.4%-9.9%-7.2%6.8%0%14.8%-13%-15.7%-14.6%-
Adj EPS ⓘ2.50.20.40.50.40.71.810.40.31.6
YoY Gr.--91.1%86.4%26.8%-26.9%94.7%146%-47.3%-56.3%-28.6%-
BVPS (₹) ⓘ20.826.224.629.526.930.632.433.433.834.137.7
Adj Net
Profit ⓘ		1.80.20.30.40.30.71.60.90.40.32
Cash Flow from Ops. ⓘ3.61.76.91.22.51.60.82.223.2-
Debt/CF from Ops. ⓘ5.59.128.23.9821.277.65.4-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ-3.5%-6.4%-14.4%-14.6%
Adj EPS ⓘ-20.9%-4.6%-45.2%-28.6%
BVPSⓘ5.7%4.9%1.7%0.9%
Share Price 2.9% 19.8% 33.3% 18.3%

Key Financial Parameters ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		12.60.91.71.91.42.65.831.30.94.3
Op. Profit
Mgn % ⓘ		16.49.68.87.66.56.39.58.58.510.26.7
Net Profit
Mgn % ⓘ		3.50.30.60.90.61.32.71.710.82.5
Debt to
Equity ⓘ		1.30.80.70.40.40.50.60.50.40.5-
Working Cap
Days ⓘ		263251474620416293241296348414118
Cash Conv.
Cycle ⓘ		12810212914619921718921724228354

Valuation of Concord Drugs - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales59524545
Operating Expenses ⓘ + 53484141
Manufacturing Costs161377
Material Costs27292729
Employee Cost 4454
Other Costs ⓘ 7222
Operating Profit ⓘ 6544
Operating Profit Margin (%) 9.5%8.8%9.0%9.1%
Other Income ⓘ + 0000
Exceptional Items ⓘ 0000
Interest ⓘ 2222
Depreciation ⓘ 2221
Profit Before Tax ⓘ 2111
Tax ⓘ 1000
Profit After Tax 2100
PAT Margin (%) 2.7%1.9%1.1%0.7%
Adjusted EPS (₹)1.81.10.50.3
Dividend Payout Ratio (%)0%0%0%0%
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 28313434
Share Capital ⓘ 8.749.321010
Reserves ⓘ 20222424
Debt +16161717
Long Term Debt2211
Short Term Debt14141616
Minority Interest0000
Trade Payables7538
Others Liabilities ⓘ 5656
Total Liabilities ⓘ 56585965

Fixed Assets

Net Fixed Assets ⓘ +13121112
Gross Block37123739
Accumulated Depreciation2302628
CWIP ⓘ 1122
Investments ⓘ 0111
Inventories17202325
Trade Receivables23161314
Cash Equivalents 0000
Others Assets ⓘ 28912
Total Assets ⓘ 56585965
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 1214
PBT ⓘ 2111
Adjustment ⓘ 3333
Changes in Working Capital ⓘ -4-2-3-0
Tax Paid ⓘ -1-0-0-0
Cash Flow From Investing Activity ⓘ + -2-2-1-2
Capex -2-1-1-2
Net Investments 0-100
Others ⓘ 0000
Cash Flow From Financing Activity ⓘ + 210-1
Net Proceeds from Shares ⓘ 0210
Net Proceeds from Borrowing ⓘ -1-0-11
Interest Paid ⓘ -1-2-2-2
Dividend Paid ⓘ 0000
Others ⓘ 403-0
Net Cash Flow ⓘ 000-0
PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)5.623.311.450.99
ROCE (%)8.776.324.995.19
Asset Turnover Ratio1.040.910.770.73
PAT to CFO Conversion(x)0.52N/AN/A
Working Capital Days
Receivable Days141.50135.50115.90106.20
Inventory Days108.30131.60174.60194.40
Payable Days96.907856.6067.30

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Concord Drugs Ltd FAQs

The current trading price of Concord Drugs on 25-Sep-2026 16:59 is ₹78.33.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of Concord Drugs stood at ₹103.2 Cr

The latest P/E ratio of Concord Drugs as of 24-Sep-2026 is 50.66.

The latest P/B ratio of Concord Drugs as of 24-Sep-2026 is 2.08.

The 52-week high of Concord Drugs is ₹92.52 and the 52-week low is ₹61.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Concord Drugs is ₹83.35 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Concord Drugs Ltd is a below average quality company.

The key valuation ratios of Concord Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Concord Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Concord Drugs Ltd

No data to display
You have 40 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now